BriaCell (BCTX) Therapeutics announces that its subsidiary, BriaPro Therapeutics, has initiated a research collaboration with Receptor.AI, an AI-driven drug discovery company, to design anti-cancer isoform-selective kinase inhibitors for multiple cancer indications. The collaboration will integrate AI-driven molecular design expertise and BriaPro’s proprietary technology to expand BriaPro’s small-molecule pipeline and accelerate the development of selective kinase inhibitors that may enhance immune-mediated tumor targeting and improve cancer patient outcomes. “This partnership marks an important step in BriaCell’s strategic expansion beyond cell-based immunotherapy into small-molecule discovery, reinforcing its mission to deliver differentiated and complementary approaches to cancer treatment,” stated Dr. William Williams, President and CEO of BriaCell and BriaPro.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BCTX:
- BriaCell to Present Key Clinical Data at SABCS 2025
- BriaCell Unveils Promising Anti-Cancer Data for Bria-OTS+ Platform
- BriaCell presents anti-cancer activity of Bria-OTS at SITC 2025
- BriaCell to Showcase Promising Cancer Immunotherapy Platform at SITC Meeting
- BriaCell’s Phase 3 Study in Metastatic Breast Cancer Receives Positive DSMB Recommendation